Deubiquitinating enzyme VCIP135 dictates the duration of botulinum neurotoxin type A intoxication

Proceedings of the National Academy of Sciences of the United States of America

Volumn 114, Issue 26, 2017, Pages E5158-E5166

  Tsai, Yien Che ^a   Kotiy, Archana ^b,c   Kiris, Erkan ^a,d   Yang, Mei ^a   Bavari, Sina ^d   Tessarollo, Lino ^a   Oyler, George A ^b,c   Weissman, Allan M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Johns Hopkins University   (United States)

^c SYNAPTIC RESEARCH LLC   (United States)

^d UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

Author keywords

Motoneuron; Synaptic transmission; Synaptosomal Associated protein 25; Toxin persistence; USP9X

Indexed keywords

AMINO ACID; BOTULINUM TOXIN A; CELL PROTEIN; DEUBIQUITINASE; DOXYCYCLINE; EPOXOMICIN; HECTD2 PROTEIN; PROTEASOME; SYNAPTOSOMAL ASSOCIATED PROTEIN 25; UBIQUITIN LIGASE HECTD2; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG; VALOSIN CONTAINING PROTEIN; VALOSIN CONTAINING PROTEIN COMPLEX INTERACTING PROTEIN 135 KDA; ENZYME INHIBITOR; HECTD2 PROTEIN, HUMAN; HECTD2 PROTEIN, MOUSE; PROTEINASE; SNAP25 PROTEIN, HUMAN; SNAP25 PROTEIN, MOUSE; VCIP135 PROTEIN, HUMAN;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; AUTOPHAGY; BOTULISM; CARBOXY TERMINAL SEQUENCE; CATALYSIS; CELL DIFFERENTIATION; CONTROLLED STUDY; DISEASE DURATION; ENZYME BINDING; ENZYME DEGRADATION; ENZYME STABILITY; ENZYME SUBSTRATE; HEK293 CELL LINE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; LIGHT CHAIN; MOTONEURON; MOUSE; MOUSE EMBRYONIC STEM CELL; NEUROBLASTOMA CELL LINE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN DOMAIN; PROTEIN SYNTHESIS; SYNAPTIC TRANSMISSION; TURNOVER TIME; UBIQUITINATION; ANIMAL; CHEMISTRY; CYTOLOGY; GENETICS; METABOLISM;

ANIMALS; BOTULINUM TOXINS, TYPE A; ENDOPEPTIDASES; ENZYME INHIBITORS; HEK293 CELLS; HUMANS; MICE; MOUSE EMBRYONIC STEM CELLS; SYNAPTOSOMAL-ASSOCIATED PROTEIN 25; UBIQUITIN-PROTEIN LIGASES;

EID: 85021428174     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1621076114     Document Type: Article

References (44)

1. Simpson LL (2000) Identification of the characteristics that underlie botulinum toxin potency: Implications for designing novel drugs. Biochimie 82:943-953.
2. Habermann E, Dreyer F (1986) Clostridial neurotoxins: Handling and action at the cellular and molecular level. Curr Top Microbiol Immunol 129:93-179.
3. Johnson EA, Montecucco C (2008) Botulism. Handb Clin Neurol 91:333-368.
4. Schiavo G, Matteoli M, Montecucco C (2000) Neurotoxins affecting neuroexocytosis. Physiol Rev 80:717-766.
5. Montecucco C, Schiavo G (1995) Structure and function of tetanus and botulinum neurotoxins. Q Rev Biophys 28:423-472.
6. Dolly JO, Black J, Williams RS, Melling J (1984) Acceptors for botulinum neurotoxin reside on motor nerve terminals and mediate its internalization. Nature 307:457-460.
7. Pantano S, Montecucco C (2014) The blockade of the neurotransmitter release apparatus by botulinum neurotoxins. Cell Mol Life Sci 71:793-811.
8. Arnon SS, et al.; Working Group on Civilian Biodefense (2001) Botulinum toxin as a biological weapon: Medical and public health management. JAMA 285:1059-1070.
9. Eleopra R, Tugnoli V, Rossetto O, De Grandis, D, Montecucco C (1998) Different time courses of recovery after poisoning with botulinum neurotoxin serotypes A and E in humans. Neurosci Lett 256:135-138.
10. Shoemaker CB, Oyler GA (2013) Persistence of Botulinum neurotoxin inactivation of nerve function. Curr Top Microbiol Immunol 364:179-196.
11. Rossetto O, Pirazzini M, Montecucco C (2014) Botulinum neurotoxins: Genetic, structural and mechanistic insights. Nat Rev Microbiol 12:535-549.
12. Tsai YC, et al. (2010) Targeting botulinum neurotoxin persistence by the ubiquitinproteasome system. Proc Natl Acad Sci USA 107:16554-16559.
13. Keller JE, Neale EA, Oyler G, Adler M (1999) Persistence of botulinum neurotoxin action in cultured spinal cord cells. FEBS Lett 456:137-142.
14. Whitemarsh RC, Tepp WH, Johnson EA, Pellett S (2014) Persistence of botulinum neurotoxin a subtypes 1-5 in primary rat spinal cord cells. PLoS One 9:e90252.
15. Binz T, et al. (1994) Proteolysis of SNAP-25 by types E and A botulinal neurotoxins. J Biol Chem 269:1617-1620.
16. Tsai YC, et al. (2012) Differential regulation of HMG-CoA reductase and Insig-1 by enzymes of the ubiquitin-proteasome system. Mol Biol Cell 23:4484-4494.
17. Semizarov D, et al. (2003) Specificity of short interfering RNA determined through gene expression signatures. Proc Natl Acad Sci USA 100:6347-6352.
18. Jackson AL, et al. (2003) Expression profiling reveals off-Target gene regulation by RNAi. Nat Biotechnol 21:635-637.
19. DiAntonio A, et al. (2001) Ubiquitination-dependent mechanisms regulate synaptic growth and function. Nature 412:449-452.
20. Rott R, et al. (2011) α-Synuclein fate is determined by USP9X-regulated monoubiquitination. Proc Natl Acad Sci USA 108:18666-18671.
21. Grasso D, et al. (2011) Zymophagy, a novel selective autophagy pathway mediated by VMP1-USP9x-p62, prevents pancreatic cell death. J Biol Chem 286:8308-8324.
22. Thomas RL, Gustafsson AB (2013) MCL1 is critical for mitochondrial function and autophagy in the heart. Autophagy 9:1902-1903.
23. Germain M, et al. (2011) MCL-1 is a stress sensor that regulates autophagy in a developmentally regulated manner. EMBO J 30:395-407.
24. Schwickart M, et al. (2010) Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. Nature 463:103-107.
25. Nagai H, et al. (2009) Ubiquitin-like sequence in ASK1 plays critical roles in the recognition and stabilization by USP9X and oxidative stress-induced cell death. Mol Cell 36:805-818.
26. Naik E, et al. (2014) Regulation of proximal T cell receptor signaling and tolerance induction by deubiquitinase Usp9X. J Exp Med 211:1947-1955.
27. Wang Y, Satoh A, Warren G, Meyer HH (2004) VCIP135 acts as a deubiquitinating enzyme during p97-p47-mediated reassembly of mitotic Golgi fragments. J Cell Biol 164:973-978.
28. Uchiyama K, et al. (2002) VCIP135, a novel essential factor for p97/p47-mediated membrane fusion, is required for Golgi and ER assembly in vivo. J Cell Biol 159: 855-866.
29. Kano F, et al. (2005) NSF/SNAPs and p97/p47/VCIP135 are sequentially required for cell cycle-dependent reformation of the ER network. Genes Cells 10:989-999.
30. Totsukawa G, et al. (2011) VCIP135 deubiquitinase and its binding protein, WAC, in p97ATPase-mediated membrane fusion. EMBO J 30:3581-3593.
31. Chen S, Barbieri JT (2011) Association of botulinum neurotoxin serotype A light chain with plasma membrane-bound SNAP-25. J Biol Chem 286:15067-15072.
32. Coon TA, et al. (2015) The proinflammatory role of HECTD2 in innate immunity and experimental lung injury. Sci Transl Med 7:295ra109.
33. Lloyd SE, et al. (2009) HECTD2 is associated with susceptibility to mouse and human prion disease. PLoS Genet 5:e1000383.
34. Lloyd SE, Rossor M, Fox N, Mead S, Collinge J (2009) HECTD2, a candidate susceptibility gene for Alzheimer's disease on 10q. BMC Med Genet 10:90.
35. Duregotti E, et al. (2015) Snake and spider toxins induce a rapid recovery of function of botulinum neurotoxin paralysed neuromuscular junction. Toxins (Basel) 7: 5322-5336.
36. Foran PG, et al. (2003) Evaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, E, and F compared with the long lasting type A. Basis for distinct durations of inhibition of exocytosis in central neurons. in J Biol Chem 278:1363-1371.
37. O'Sullivan GA, Mohammed N, Foran PG, Lawrence GW, Oliver Dolly J (1999) Rescue of exocytosis in botulinum toxin A-poisoned chromaffin cells by expression of cleavageresistant SNAP-25. Identification of the minimal essential C-Terminal residues. J Biol Chem 274:36897-36904.
38. Kiris E, et al. (2011) Embryonic stem cell-derived motoneurons provide a highly sensitive cell culture model for botulinum neurotoxin studies, with implications for highthroughput drug discovery. Stem Cell Res (Amst) 6:195-205.
39. Hanig JP, Lamanna C (1979) Toxicity of botulinum toxin: A stoichiometric model for the locus of its extraordinary potency and persistence at the neuromuscular junction. J Theor Biol 77:107-113.
40. Fernández-Salas E, Ho H, Garay P, Steward LE, Aoki KR (2004) Is the light chain subcellular localization an important factor in botulinum toxin duration of action? Mov Disord 19:S23-S34.
41. Fernández-Salas E, et al. (2004) Plasma membrane localization signals in the light chain of botulinum neurotoxin. Proc Natl Acad Sci USA 101:3208-3213.
42. Kuo CL, Oyler GA, Shoemaker CB (2011) Accelerated neuronal cell recovery from Botulinum neurotoxin intoxication by targeted ubiquitination. PLoS One 6:e20352.
43. Sowa ME, Bennett EJ, Gygi SP, Harper JW (2009) Defining the human deubiquitinating enzyme interaction landscape. Cell 138:389-403.
44. Hatakeyama S, Jensen JP, Weissman AM (1997) Subcellular localization and ubiquitinconjugating enzyme (E2) interactions of mammalian HECT family ubiquitin protein ligases. J Biol Chem 272:15085-15092.